| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
FDA approves AstraZeneca's Imfinzi with chemotherapy for early-stage lung cancer, based on pivotal AEGEAN trial. Imfinzi sh...
AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy.
Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch r...
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The ...
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare d...
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating...
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monothera...
